

Resource Summary Report

Generated by [dkNET](#) on Aug 12, 2026

Pacific Blue(TM) anti-human CD3

RRID:AB_1595437

Type: Antibody

Proper Citation

BioLegend Cat# 300431, RRID:AB_1595437

Antibody Information

URL: http://antibodyregistry.org/AB_1595437

Proper Citation: BioLegend Cat# 300431, RRID:AB_1595437

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_1595437

Vendor: BioLegend

Catalog Number: 300431

Alternative Catalog Numbers: 300417, 300418, 300442

Record Creation Time: 20250820T034030+0000

Record Last Update: 20250820T165250+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD3.

No alerts have been found for Pacific Blue(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zeng Z, et al. (2026) Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med (New York, N.Y.), 101226.

McCluskey D, et al. (2025) IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus. Cell reports. Medicine, 6(8), 102247.

Zhao Z, et al. (2025) Sick cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. Immunity, 58(6), 1484.

Decker AH, et al. (2025) Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis. iScience, 28(7), 112957.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages. eLife, 13.

Kaplonek P, et al. (2023) Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines. Cell reports. Medicine, 4(5), 101048.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. Cell reports, 42(6), 112657.

Kaplonek P, et al. (2022) mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity, 55(2), 355.

Schnizer C, et al. (2022) Persistent humoral and CD4+ TH cell immunity after mild SARS-CoV-2 infection-The CoNAN long-term study. Frontiers in immunology, 13, 1095129.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. Cell, 185(8), 1414.

Andreas N, et al. (2022) Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. Vaccines, 10(1).

Weymar GHJ, et al. (2022) Distinct gene expression by expanded clones of quiescent memory CD4⁺ T cells harboring intact latent HIV-1 proviruses. *Cell reports*, 40(10), 111311.

Pullen KM, et al. (2021) Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection. *Cell reports*, 37(6), 109959.

Alter G, et al. (2020) Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. *Cell*, 183(1), 185.

Leylek R, et al. (2019) Integrated Cross-Species Analysis Identifies a Conserved Transitional Dendritic Cell Population. *Cell reports*, 29(11), 3736.

Alcántara-Hernández M, et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. *Immunity*, 47(6), 1037.